Antaros Medical presented data at the 2nd NASH biomarkers workshop on the importance of assessing the entire liver when studying liver fat
May 6th, 2017
Assoc Professor Lars Johansson, co-founder of Antaros Medical and Chief Scienctific Officer, together with Dr Chris Weyer, President and Chief Development Officer at ProSciento, presented scientific data at the 2nd International workshop on NASH Biomarkers, in Washington DC, on 5-6 May 2017.
The poster presentation titled “On the Importance of Assessing the Entire Liver in MRI-PDFF Studies of Liver Fat” summarizes data from a clinical study conducted at Uppsala University to assess changes in liver fat and liver volume following caloric restriction in subjects with morbid obesity. Analysis of fat fraction (%) using a single or multiple region of interest (ROI) approach was compared to analysis across the entire liver using a semi-automated approach developed by Antaros. Results point to several advantages of the later, including improved precision and simultaneous assessment of liver volume, as a means to control for confounders such as liver glycogen and water content. These findings have potential implications for the assessment of liver fat in pharmaceutical intervention studies, including sample size requirements.
About the 2nd International NASH Biomarkers Workshop
The NASH Biomarkers Workshop is an international cross-disciplinary forum that brings together clinical and translational research experts for in-depth discussions of the latest advances in the development of biomarkers for NASH. The NASH Biomarkers Workshop is co-organized by the Liver Forum and Expert Medical Events.
For more information, visit http://expertmedicalevents.com/event/upcoming/nash-biomarkers-2017/.
Back to all news